secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-09-19T23:59:59+00:00
Accession:  0001213900-25-089584
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress
--------------------------------------------------------------------------------

- Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.
- BEACON CSU investigation rules out drug substance/product issues; focus shifts to clinical site activity.
- Investigation completion expected in Q4 2025 with KOL panel review for Phase 2b CSU study integration.
- Use of proceeds: continued development of briquilimab in mast-cell diseases and general corporate expenses.
- Common warrants exercisable at $2.92, 6-month lockout, 4-year term; pre-funded warrants at $0.0001 exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/0001213900-25-089584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025089584/ea0258026-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-089584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer